Cellestis posts strong result
Wednesday, 26 August, 2009
Melbourne-based CSL spin-off, Cellestis, has demonstrated that it's not all bad news in today's economic climate by posting record sales and profits for the 2009 financial year.
Cellestis is best known for its tuberculosis (TB) diagnostic, QuantiFERON, which it markets here and overseas.
Revenues were up 83 per cent to $34.5 million, with a record profit of $8.2 million.
According to CEO, Dr Tony Radford, sales were strong in all markets, including the UK, Europe, Japan and the US. The profits will be reinvested in to sales and marketing as well as research and development of new products.
Cellestis's (ASX:CST) share price took a small dip after the announcement, dropping as much as 16 per cent at one point, but it bounced back to $3.65 at the opening of Wednesday's trading.
Shingles vaccine may lower risk of dementia, heart disease
It turns out that the shingles vaccine may have public-health benefits beyond its intended...
How does the brain evaluate rewards?
Neuroscientists have shown how nerve cells in the amygdala not only encode the probability and...
Breakthrough drug prevents long COVID symptoms in mice
Mice treated with the antiviral compound were protected from long-term brain and lung dysfunction...
